Related Experiment Video

Updated: Apr 26, 2026

Author Spotlight: Assessing Intrathecal Gene Therapy Efficacy in Juvenile Rats
04:38

Author Spotlight: Assessing Intrathecal Gene Therapy Efficacy in Juvenile Rats

Published on: March 29, 2024

1.9K

Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Heinrike Schmeling1, Gerd Horneff2, Susanne M Benseler1

  • 1Alberta Children's Hospital Research Institute, University of Calgary, Heritage Medical Research Building, Room 293, 3330 Hospital Drive, NW, Calgary, AB T2N 4N1, Canada.

Nature Reviews. Rheumatology
|August 13, 2014
PubMed

Insights

Juvenile idiopathic arthritis (JIA) treatment response lacks predictive biomarkers. Genome-wide studies in JIA aim to identify genetic factors for personalized medicine, improving drug efficacy and reducing adverse effects.

Area of Science:

  • Pediatric Rheumatology
  • Pharmacogenomics
  • Genetics

Background:

  • Juvenile idiopathic arthritis (JIA) is a common childhood rheumatic disease requiring long-term immunomodulatory therapy.
  • Many children face treatment inefficacy or adverse effects due to a lack of predictive biomarkers.
  • Previous candidate gene studies for JIA pharmacogenetics have yielded limited success.

Purpose of the Study:

  • To identify reliable clinical indicators and biomarkers for predicting treatment response in JIA.
  • To explore genetic variations influencing responses to methotrexate and etanercept in JIA patients.
  • To advance personalized medicine approaches for JIA treatment.

Main Methods:

  • Genome-wide pharmacogenetic analysis in JIA cohorts.
  • Investigation of candidate gene variants in methotrexate and etanercept pathways.
  • Analysis of epigenetic mechanisms and ontogeny processes influencing drug response.

Main Results:

  • The first genome-wide pharmacogenetic study in JIA identified biologically relevant gene regions requiring validation.
  • Limited success in identifying specific gene variants for methotrexate and etanercept response.
  • Confounding variables and heterogeneity in previous studies may explain limited findings.

Conclusions:

  • Personalized treatment for JIA is emerging with large cohorts and advanced genomic analytics.
  • Discovery of pharmacogenomic biomarkers and pathways can lead to improved drug targeting and predictive tools.
  • Future research should focus on validating genome-wide findings and exploring epigenetic factors for optimized JIA therapy.

More Related Videos

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.5K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
241
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
328